This mutation has also been detected in NSCLC patients before EGFR-TKI treatment, however, with a detection rate ranging from ~30% to ~80% depending on the sensitivity of the detection technique [16-19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.